Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.94 USD
+0.04 (1.03%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RPTX 3.94 +0.04(1.03%)
Will RPTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPTX
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Other News for RPTX
Repare Therapeutics management to meet virtually with Piper Sandler
Buy Rating Affirmed for Repare Therapeutics on Promising Pipeline and Strategic Advantages
TD Cowen Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics announces intial data from Phase 1 MINOTAUR trial